Document Detail


FCGR2A/CD32A and FCGR3A/CD16A Variants and EULAR Response to Tumor Necrosis Factor-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup.
MedLine Citation:
PMID:  22467926     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: The efficacy of antibody-based biological therapies currently used in psoriatic arthritis (PsA) depends not only on their blocking effect on the targeted molecule but also on their binding affinity to genetically defined variants of cell-surface Fc-γ receptors. Our objective was to assess the potential influence of functionally relevant FCGR2A/CD32A (H131R) and FCGR3A/CD16A (V158F) genetic polymorphisms on the EULAR response to tumor necrosis factor-α (TNF-α) blocker therapy in PsA. METHODS: In total 103 patients with PsA starting anti-TNF-α therapy were included. The efficacy of therapy was evaluated according to EULAR response criteria at 3 and 6 months. FCGR2A-R131H and FCGR3A-F158V polymorphisms were genotyped. Potential correlations between clinical response and the FCGR2A-R131H and FCGR3A-F158V polymorphisms were evaluated. RESULTS: EULAR response (moderate plus good) was 85.4% at 3 months and 87.4% at 6 months, while good EULAR response was 61.2% and 62.1%, respectively. More patients with high-affinity FCGR2A genotypes (homozygous or heterozygous combinations) achieved a EULAR response at 6 months compared to patients with the low-affinity genotype (RR; p = 0.034, adjusted comparison error rate < 0.025). This association was due mainly to the group of patients treated with etanercept. No correlation was found for the FCGR3A polymorphism. Similarly, no effect of C-reactive protein levels was observed. CONCLUSION: Our data indicate that FCGR2A polymorphism may influence the response to TNF-α blockers (namely etanercept) in PsA in a direction opposite to that previously found in patients with rheumatoid arthritis.
Authors:
Julio Ramírez; José Luis Fernández-Sueiro; Raquel López-Mejías; Carlos Montilla; Maite Arias; Concepción Moll; Mercé Alsina; Raimon Sanmarti; Francisco Lozano; Juan D Cañete
Related Documents :
23225026 - Recombinant human epidermal growth factor on oral mucositis induced by intensive chemot...
9823396 - Laparoscopic versus open splenectomy in the management of splenomegaly: our preliminary...
19285296 - Small stitches with small suture distances increase laparotomy closure strength.
10663826 - Effects of carotid artery repair following neonatal extracorporeal membrane oxygenation.
11803326 - Quality of life after cardiac surgery in the elderly.
3893666 - Management of chronic perineal sinuses by wide excision and split-thickness skin grafting.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-1
Journal Detail:
Title:  The Journal of rheumatology     Volume:  -     ISSN:  0315-162X     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
From the Department of Rheumatology, Arthritis Unit, Department of Immunology, Innate Immunity Unit, and Department of Dermatology, Hospital Clínic, Barcelona; Department of Rheumatology, Hospital Juan Canalejo, La Coruña; Department of Rheumatology, Hospital Clínico, Salamanca; Department of Cellular Biology, Immunology and Neurosciences, University of Barcelona, Barcelona; and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High-dose Intravenous Immunoglobulin Treatment Increases Regulatory T Cells in Patients with Eosinop...
Next Document:  Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor age...